We also recognize a limitation that the mechanisms of NF-κB and STAT3 on regulating the SLC7A11/GSH/GPX4 antioxidant axis and XJS targeting FGL1 to inhibit colitis are not verified in vitro, which will be conducted in a future study. This evidence concerns the gene FGL1 and colitis.